BCM
ANIX icon

Brookstone Capital Management’s Anixa Biosciences ANIX Stock Holding History

Brookstone Capital Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-80
Closed – – 195
2015
Q3 		$0 Buy
+80
New +$372 ﹤0.01% 1977

Other funds holding ANIX

BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DIA
Denver Investment Advisors Denver, Colorado $1.89B AUM 7.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Brookstone Capital Management's ANIX Position: Q4 2015 in Review

Brookstone Capital Management sold out of Anixa Biosciences (ANIX) in Q4 2015, closing a stake of 80 shares.

Brookstone Capital Management first reported a position in ANIX in Q3 2015 and held it in 1 quarter. The position peaked at $0 in Q3 2015. 17 funds tracked by Wall St. Rank hold ANIX as of Q4 2015.

  • Brookstone Capital Management reported no remaining Anixa Biosciences position as of Q4 2015 after selling out during the quarter.
  • Brookstone Capital Management sold 80 Anixa Biosciences shares in Q4 2015.
  • Brookstone Capital Management first reported a position in Anixa Biosciences in Q3 2015 and held it in 1 quarter.
  • Brookstone Capital Management's Anixa Biosciences position peaked at $0 in Q3 2015.
  • 17 funds tracked by Wall St. Rank held Anixa Biosciences as of Q4 2015.

Based on Brookstone Capital Management's 13F filing for Q4 2015, filed 14 Jan 2016.